APO Research
Talk to an analyst

APO RESEARCH · REPORT

Prostate Cancer Vaccines

Compare research editions
View pricing & licenses

Selected research

Industry Research

Prostate Cancer Vaccines Industry Research Report 2026

19 December 2025130 pages

Choose your research edition.

Industry ResearchProstate Cancer Vaccines Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Prostate Cancer Vaccines Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Prostate Cancer Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prostate Cancer Vaccines Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Prostate Cancer Vaccines Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Prostate Cancer Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Prostate Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Prostate Cancer Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Prostate Cancer Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Prostate Cancer Vaccines include Pfizer Inc., Vaccitech, Vaccibody AS, Ultimovacs, UbiVac, SOTIO, Sensei Biotherapeutics, Oncovir Inc. and OncBioMune Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Prostate Cancer Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Prostate Cancer Vaccines Market by Company

Pfizer Inc.

Vaccitech

Vaccibody AS

Ultimovacs

UbiVac

SOTIO

Sensei Biotherapeutics

Oncovir Inc.

OncBioMune Pharmaceuticals

Momotaro-Gene Inc.

Mediolanum Farmaceutici

Medigene AG

Dendreon Corporation

Curevac AG

Cleveland BioLabs Inc.

Bavarian Nordic

AlphaVax Inc.

Advaxis immunotherapies

Advantagene

Prostate Cancer Vaccines Segment by Type

Tablet

Injection

Prostate Cancer Vaccines Segment by Application

Hospital

Clinic

Others

Prostate Cancer Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Prostate Cancer Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Prostate Cancer Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Prostate Cancer Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Prostate Cancer Vaccines Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Prostate Cancer Vaccines Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Prostate Cancer Vaccines Sales Market Share by Manufacturers (2021-2026) Table 8. Global Prostate Cancer Vaccines Revenue of Manufacturers (2021-2026) Table 9. Global Prostate Cancer Vaccines Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Prostate Cancer Vaccines Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Prostate Cancer Vaccines Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Prostate Cancer Vaccines, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Prostate Cancer Vaccines, Product Type & Application Table 14. Global Prostate Cancer Vaccines Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Prostate Cancer Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Pfizer Inc. Company Information Table 19. Pfizer Inc. Business Overview Table 20. Pfizer Inc. Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Pfizer Inc. Prostate Cancer Vaccines Product Portfolio Table 22. Pfizer Inc. Recent Developments Table 23. Vaccitech Company Information Table 24. Vaccitech Business Overview Table 25. Vaccitech Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Vaccitech Prostate Cancer Vaccines Product Portfolio Table 27. Vaccitech Recent Developments Table 28. Vaccibody AS Company Information Table 29. Vaccibody AS Business Overview Table 30. Vaccibody AS Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Vaccibody AS Prostate Cancer Vaccines Product Portfolio Table 32. Vaccibody AS Recent Developments Table 33. Ultimovacs Company Information Table 34. Ultimovacs Business Overview Table 35. Ultimovacs Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Ultimovacs Prostate Cancer Vaccines Product Portfolio Table 37. Ultimovacs Recent Developments Table 38. UbiVac Company Information Table 39. UbiVac Business Overview Table 40. UbiVac Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. UbiVac Prostate Cancer Vaccines Product Portfolio Table 42. UbiVac Recent Developments Table 43. SOTIO Company Information Table 44. SOTIO Business Overview Table 45. SOTIO Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. SOTIO Prostate Cancer Vaccines Product Portfolio Table 47. SOTIO Recent Developments Table 48. Sensei Biotherapeutics Company Information Table 49. Sensei Biotherapeutics Business Overview Table 50. Sensei Biotherapeutics Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sensei Biotherapeutics Prostate Cancer Vaccines Product Portfolio Table 52. Sensei Biotherapeutics Recent Developments Table 53. Oncovir Inc. Company Information Table 54. Oncovir Inc. Business Overview Table 55. Oncovir Inc. Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Oncovir Inc. Prostate Cancer Vaccines Product Portfolio Table 57. Oncovir Inc. Recent Developments Table 58. OncBioMune Pharmaceuticals Company Information Table 59. OncBioMune Pharmaceuticals Business Overview Table 60. OncBioMune Pharmaceuticals Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. OncBioMune Pharmaceuticals Prostate Cancer Vaccines Product Portfolio Table 62. OncBioMune Pharmaceuticals Recent Developments Table 63. Momotaro-Gene Inc. Company Information Table 64. Momotaro-Gene Inc. Business Overview Table 65. Momotaro-Gene Inc. Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Momotaro-Gene Inc. Prostate Cancer Vaccines Product Portfolio Table 67. Momotaro-Gene Inc. Recent Developments Table 68. Mediolanum Farmaceutici Company Information Table 69. Mediolanum Farmaceutici Business Overview Table 70. Mediolanum Farmaceutici Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Mediolanum Farmaceutici Prostate Cancer Vaccines Product Portfolio Table 72. Mediolanum Farmaceutici Recent Developments Table 73. Medigene AG Company Information Table 74. Medigene AG Business Overview Table 75. Medigene AG Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Medigene AG Prostate Cancer Vaccines Product Portfolio Table 77. Medigene AG Recent Developments Table 78. Dendreon Corporation Company Information Table 79. Dendreon Corporation Business Overview Table 80. Dendreon Corporation Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Dendreon Corporation Prostate Cancer Vaccines Product Portfolio Table 82. Dendreon Corporation Recent Developments Table 83. Curevac AG Company Information Table 84. Curevac AG Business Overview Table 85. Curevac AG Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Curevac AG Prostate Cancer Vaccines Product Portfolio Table 87. Curevac AG Recent Developments Table 88. Cleveland BioLabs Inc. Company Information Table 89. Cleveland BioLabs Inc. Business Overview Table 90. Cleveland BioLabs Inc. Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Cleveland BioLabs Inc. Prostate Cancer Vaccines Product Portfolio Table 92. Cleveland BioLabs Inc. Recent Developments Table 93. Bavarian Nordic Company Information Table 94. Bavarian Nordic Business Overview Table 95. Bavarian Nordic Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Bavarian Nordic Prostate Cancer Vaccines Product Portfolio Table 97. Bavarian Nordic Recent Developments Table 98. AlphaVax Inc. Company Information Table 99. AlphaVax Inc. Business Overview Table 100. AlphaVax Inc. Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. AlphaVax Inc. Prostate Cancer Vaccines Product Portfolio Table 102. AlphaVax Inc. Recent Developments Table 103. Advaxis immunotherapies Company Information Table 104. Advaxis immunotherapies Business Overview Table 105. Advaxis immunotherapies Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Advaxis immunotherapies Prostate Cancer Vaccines Product Portfolio Table 107. Advaxis immunotherapies Recent Developments Table 108. Advantagene Company Information Table 109. Advantagene Business Overview Table 110. Advantagene Prostate Cancer Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Advantagene Prostate Cancer Vaccines Product Portfolio Table 112. Advantagene Recent Developments Table 113. Global Prostate Cancer Vaccines Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global Prostate Cancer Vaccines Sales by Region (2021-2026) & (K Units) Table 115. Global Prostate Cancer Vaccines Sales Market Share by Region (2021-2026) Table 116. Global Prostate Cancer Vaccines Sales by Region (2027-2032) & (K Units) Table 117. Global Prostate Cancer Vaccines Sales Market Share by Region (2027-2032) Table 118. Global Prostate Cancer Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 119. Global Prostate Cancer Vaccines Revenue Market Share by Region (2021-2026) Table 120. Global Prostate Cancer Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 121. Global Prostate Cancer Vaccines Revenue Market Share by Region (2027-2032) Table 122. North America Prostate Cancer Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America Prostate Cancer Vaccines Sales by Country (2021-2026) & (K Units) Table 124. North America Prostate Cancer Vaccines Sales by Country (2027-2032) & (K Units) Table 125. North America Prostate Cancer Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Prostate Cancer Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe Prostate Cancer Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe Prostate Cancer Vaccines Sales by Country (2021-2026) & (K Units) Table 129. Europe Prostate Cancer Vaccines Sales by Country (2027-2032) & (K Units) Table 130. Europe Prostate Cancer Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe Prostate Cancer Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific Prostate Cancer Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific Prostate Cancer Vaccines Sales by Country (2021-2026) & (K Units) Table 134. Asia Pacific Prostate Cancer Vaccines Sales by Country (2027-2032) & (K Units) Table 135. Asia Pacific Prostate Cancer Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific Prostate Cancer Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 137. South America Prostate Cancer Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America Prostate Cancer Vaccines Sales by Country (2021-2026) & (K Units) Table 139. South America Prostate Cancer Vaccines Sales by Country (2027-2032) & (K Units) Table 140. South America Prostate Cancer Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 141. South America Prostate Cancer Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Prostate Cancer Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa Prostate Cancer Vaccines Sales by Country (2021-2026) & (K Units) Table 144. Middle East and Africa Prostate Cancer Vaccines Sales by Country (2027-2032) & (K Units) Table 145. Middle East and Africa Prostate Cancer Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa Prostate Cancer Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 147. Global Prostate Cancer Vaccines Sales by Type (2021-2026) & (K Units) Table 148. Global Prostate Cancer Vaccines Sales by Type (2027-2032) & (K Units) Table 149. Global Prostate Cancer Vaccines Sales Market Share by Type (2021-2026) Table 150. Global Prostate Cancer Vaccines Sales Market Share by Type (2027-2032) Table 151. Global Prostate Cancer Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 152. Global Prostate Cancer Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 153. Global Prostate Cancer Vaccines Revenue Market Share by Type (2021-2026) Table 154. Global Prostate Cancer Vaccines Revenue Market Share by Type (2027-2032) Table 155. Global Prostate Cancer Vaccines Price by Type (2021-2026) & (US$/Unit) Table 156. Global Prostate Cancer Vaccines Price by Type (2027-2032) & (US$/Unit) Table 157. Global Prostate Cancer Vaccines Sales by Application (2021-2026) & (K Units) Table 158. Global Prostate Cancer Vaccines Sales by Application (2027-2032) & (K Units) Table 159. Global Prostate Cancer Vaccines Sales Market Share by Application (2021-2026) Table 160. Global Prostate Cancer Vaccines Sales Market Share by Application (2027-2032) Table 161. Global Prostate Cancer Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 162. Global Prostate Cancer Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 163. Global Prostate Cancer Vaccines Revenue Market Share by Application (2021-2026) Table 164. Global Prostate Cancer Vaccines Revenue Market Share by Application (2027-2032) Table 165. Global Prostate Cancer Vaccines Price by Application (2021-2026) & (US$/Unit) Table 166. Global Prostate Cancer Vaccines Price by Application (2027-2032) & (US$/Unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Prostate Cancer Vaccines Distributors List Table 170. Prostate Cancer Vaccines Customers List Table 171. Prostate Cancer Vaccines Industry Trends Table 172. Prostate Cancer Vaccines Industry Drivers Table 173. Prostate Cancer Vaccines Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Prostate Cancer Vaccines Product Image Figure 5. Global Prostate Cancer Vaccines Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Prostate Cancer Vaccines Market Size (2021-2032) & (US$ Million) Figure 7. Global Prostate Cancer Vaccines Sales (2021-2032) & (K Units) Figure 8. Global Prostate Cancer Vaccines Average Price (US$/Unit) & (2021-2032) Figure 9. Tablet Product Image Figure 10. Injection Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Others Product Image Figure 14. Global Prostate Cancer Vaccines Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Prostate Cancer Vaccines, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Prostate Cancer Vaccines Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Prostate Cancer Vaccines Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Prostate Cancer Vaccines Sales by Region in 2025 Figure 20. Global Prostate Cancer Vaccines Revenue by Region in 2025 Figure 21. North America Prostate Cancer Vaccines Market Size by Country in 2025 Figure 22. North America Prostate Cancer Vaccines Sales Market Share by Country (2021-2032) Figure 23. North America Prostate Cancer Vaccines Revenue Market Share by Country (2021-2032) Figure 24. United States Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Prostate Cancer Vaccines Market Size by Country in 2025 Figure 27. Europe Prostate Cancer Vaccines Sales Market Share by Country (2021-2032) Figure 28. Europe Prostate Cancer Vaccines Revenue Market Share by Country (2021-2032) Figure 29. Germany Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Netherlands Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Asia Pacific Prostate Cancer Vaccines Market Size by Country in 2025 Figure 35. Asia Pacific Prostate Cancer Vaccines Sales Market Share by Country (2021-2032) Figure 36. Asia Pacific Prostate Cancer Vaccines Revenue Market Share by Country (2021-2032) Figure 37. China Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Japan Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. South Korea Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. India Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Australia Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. China Taiwan Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South America Prostate Cancer Vaccines Market Size by Country in 2025 Figure 46. South America Prostate Cancer Vaccines Sales Market Share by Country (2021-2032) Figure 47. South America Prostate Cancer Vaccines Revenue Market Share by Country (2021-2032) Figure 48. Mexico Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Brazil Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Argentina Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Middle East and Africa Prostate Cancer Vaccines Market Size by Country in 2025 Figure 52. Middle East and Africa Prostate Cancer Vaccines Sales Market Share by Country (2021-2032) Figure 53. Middle East and Africa Prostate Cancer Vaccines Revenue Market Share by Country (2021-2032) Figure 54. Turkey Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Saudi Arabia Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. UAE Prostate Cancer Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Global Prostate Cancer Vaccines Sales Market Share by Type (2021-2032) Figure 58. Global Prostate Cancer Vaccines Revenue Market Share by Type (2021-2032) Figure 59. Global Prostate Cancer Vaccines Price (US$/Unit) by Type (2021-2032) Figure 60. Global Prostate Cancer Vaccines Sales Market Share by Application (2021-2032) Figure 61. Global Prostate Cancer Vaccines Revenue Market Share by Application (2021-2032) Figure 62. Global Prostate Cancer Vaccines Price (US$/Unit) by Application (2021-2032) Figure 63. Prostate Cancer Vaccines Value Chain Figure 64. Prostate Cancer Vaccines Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Prostate Cancer Vaccines Industry Opportunities and Challenges

Scope & coverage.

Types
  • Tablet
  • Injection
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Pfizer Inc.
  • Vaccitech
  • Vaccibody AS
  • Ultimovacs
  • UbiVac
  • SOTIO
  • Sensei Biotherapeutics
  • Oncovir Inc.
  • OncBioMune Pharmaceuticals
  • Momotaro-Gene Inc.
  • Mediolanum Farmaceutici
  • Medigene AG
  • Dendreon Corporation
  • Curevac AG
  • Cleveland BioLabs Inc.
  • Bavarian Nordic
  • AlphaVax Inc.
  • Advaxis immunotherapies
  • Advantagene

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Prostate Cancer Vaccines Market Size (2021-2032)
  4. 2.2.2 Global Prostate Cancer Vaccines Sales (2021-2032)
  5. 2.2.3 Global Prostate Cancer Vaccines Market Average Price (2021-2032)
  6. 2.3 Prostate Cancer Vaccines by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Tablet
  9. 2.3.3 Injection
  10. 2.4 Prostate Cancer Vaccines by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Prostate Cancer Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Prostate Cancer Vaccines Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Prostate Cancer Vaccines Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Prostate Cancer Vaccines Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Prostate Cancer Vaccines Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Prostate Cancer Vaccines, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Prostate Cancer Vaccines, Product Type & Application
  8. 3.8 Global Manufacturers of Prostate Cancer Vaccines, Established Date
  9. 3.9 Global Prostate Cancer Vaccines Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Pfizer Inc.
  2. 4.1.1 Pfizer Inc. Company Information
  3. 4.1.2 Pfizer Inc. Business Overview
  4. 4.1.3 Pfizer Inc. Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Pfizer Inc. Prostate Cancer Vaccines Product Portfolio
  6. 4.1.5 Pfizer Inc. Recent Developments
  7. 4.2 Vaccitech
  8. 4.2.1 Vaccitech Company Information
  9. 4.2.2 Vaccitech Business Overview
  10. 4.2.3 Vaccitech Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Vaccitech Prostate Cancer Vaccines Product Portfolio
  12. 4.2.5 Vaccitech Recent Developments
  13. 4.3 Vaccibody AS
  14. 4.3.1 Vaccibody AS Company Information
  15. 4.3.2 Vaccibody AS Business Overview
  16. 4.3.3 Vaccibody AS Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Vaccibody AS Prostate Cancer Vaccines Product Portfolio
  18. 4.3.5 Vaccibody AS Recent Developments
  19. 4.4 Ultimovacs
  20. 4.4.1 Ultimovacs Company Information
  21. 4.4.2 Ultimovacs Business Overview
  22. 4.4.3 Ultimovacs Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Ultimovacs Prostate Cancer Vaccines Product Portfolio
  24. 4.4.5 Ultimovacs Recent Developments
  25. 4.5 UbiVac
  26. 4.5.1 UbiVac Company Information
  27. 4.5.2 UbiVac Business Overview
  28. 4.5.3 UbiVac Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 UbiVac Prostate Cancer Vaccines Product Portfolio
  30. 4.5.5 UbiVac Recent Developments
  31. 4.6 SOTIO
  32. 4.6.1 SOTIO Company Information
  33. 4.6.2 SOTIO Business Overview
  34. 4.6.3 SOTIO Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 SOTIO Prostate Cancer Vaccines Product Portfolio
  36. 4.6.5 SOTIO Recent Developments
  37. 4.7 Sensei Biotherapeutics
  38. 4.7.1 Sensei Biotherapeutics Company Information
  39. 4.7.2 Sensei Biotherapeutics Business Overview
  40. 4.7.3 Sensei Biotherapeutics Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sensei Biotherapeutics Prostate Cancer Vaccines Product Portfolio
  42. 4.7.5 Sensei Biotherapeutics Recent Developments
  43. 4.8 Oncovir Inc.
  44. 4.8.1 Oncovir Inc. Company Information
  45. 4.8.2 Oncovir Inc. Business Overview
  46. 4.8.3 Oncovir Inc. Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Oncovir Inc. Prostate Cancer Vaccines Product Portfolio
  48. 4.8.5 Oncovir Inc. Recent Developments
  49. 4.9 OncBioMune Pharmaceuticals
  50. 4.9.1 OncBioMune Pharmaceuticals Company Information
  51. 4.9.2 OncBioMune Pharmaceuticals Business Overview
  52. 4.9.3 OncBioMune Pharmaceuticals Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 OncBioMune Pharmaceuticals Prostate Cancer Vaccines Product Portfolio
  54. 4.9.5 OncBioMune Pharmaceuticals Recent Developments
  55. 4.10 Momotaro-Gene Inc.
  56. 4.10.1 Momotaro-Gene Inc. Company Information
  57. 4.10.2 Momotaro-Gene Inc. Business Overview
  58. 4.10.3 Momotaro-Gene Inc. Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Momotaro-Gene Inc. Prostate Cancer Vaccines Product Portfolio
  60. 4.10.5 Momotaro-Gene Inc. Recent Developments
  61. 4.11 Mediolanum Farmaceutici
  62. 4.11.1 Mediolanum Farmaceutici Company Information
  63. 4.11.2 Mediolanum Farmaceutici Business Overview
  64. 4.11.3 Mediolanum Farmaceutici Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Mediolanum Farmaceutici Prostate Cancer Vaccines Product Portfolio
  66. 4.11.5 Mediolanum Farmaceutici Recent Developments
  67. 4.12 Medigene AG
  68. 4.12.1 Medigene AG Company Information
  69. 4.12.2 Medigene AG Business Overview
  70. 4.12.3 Medigene AG Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Medigene AG Prostate Cancer Vaccines Product Portfolio
  72. 4.12.5 Medigene AG Recent Developments
  73. 4.13 Dendreon Corporation
  74. 4.13.1 Dendreon Corporation Company Information
  75. 4.13.2 Dendreon Corporation Business Overview
  76. 4.13.3 Dendreon Corporation Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Dendreon Corporation Prostate Cancer Vaccines Product Portfolio
  78. 4.13.5 Dendreon Corporation Recent Developments
  79. 4.14 Curevac AG
  80. 4.14.1 Curevac AG Company Information
  81. 4.14.2 Curevac AG Business Overview
  82. 4.14.3 Curevac AG Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Curevac AG Prostate Cancer Vaccines Product Portfolio
  84. 4.14.5 Curevac AG Recent Developments
  85. 4.15 Cleveland BioLabs Inc.
  86. 4.15.1 Cleveland BioLabs Inc. Company Information
  87. 4.15.2 Cleveland BioLabs Inc. Business Overview
  88. 4.15.3 Cleveland BioLabs Inc. Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Cleveland BioLabs Inc. Prostate Cancer Vaccines Product Portfolio
  90. 4.15.5 Cleveland BioLabs Inc. Recent Developments
  91. 4.16 Bavarian Nordic
  92. 4.16.1 Bavarian Nordic Company Information
  93. 4.16.2 Bavarian Nordic Business Overview
  94. 4.16.3 Bavarian Nordic Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Bavarian Nordic Prostate Cancer Vaccines Product Portfolio
  96. 4.16.5 Bavarian Nordic Recent Developments
  97. 4.17 AlphaVax Inc.
  98. 4.17.1 AlphaVax Inc. Company Information
  99. 4.17.2 AlphaVax Inc. Business Overview
  100. 4.17.3 AlphaVax Inc. Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 AlphaVax Inc. Prostate Cancer Vaccines Product Portfolio
  102. 4.17.5 AlphaVax Inc. Recent Developments
  103. 4.18 Advaxis immunotherapies
  104. 4.18.1 Advaxis immunotherapies Company Information
  105. 4.18.2 Advaxis immunotherapies Business Overview
  106. 4.18.3 Advaxis immunotherapies Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Advaxis immunotherapies Prostate Cancer Vaccines Product Portfolio
  108. 4.18.5 Advaxis immunotherapies Recent Developments
  109. 4.19 Advantagene
  110. 4.19.1 Advantagene Company Information
  111. 4.19.2 Advantagene Business Overview
  112. 4.19.3 Advantagene Prostate Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Advantagene Prostate Cancer Vaccines Product Portfolio
  114. 4.19.5 Advantagene Recent Developments
5 Global Prostate Cancer Vaccines Market Scenario by Region
  1. 5.1 Global Prostate Cancer Vaccines Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Prostate Cancer Vaccines Sales by Region: 2021-2032
  3. 5.2.1 Global Prostate Cancer Vaccines Sales by Region: 2021-2026
  4. 5.2.2 Global Prostate Cancer Vaccines Sales by Region: 2027-2032
  5. 5.3 Global Prostate Cancer Vaccines Revenue by Region: 2021-2032
  6. 5.3.1 Global Prostate Cancer Vaccines Revenue by Region: 2021-2026
  7. 5.3.2 Global Prostate Cancer Vaccines Revenue by Region: 2027-2032
  8. 5.4 North America Prostate Cancer Vaccines Market Facts & Figures by Country
  9. 5.4.1 North America Prostate Cancer Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Prostate Cancer Vaccines Sales by Country (2021-2032)
  11. 5.4.3 North America Prostate Cancer Vaccines Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Prostate Cancer Vaccines Market Facts & Figures by Country
  15. 5.5.1 Europe Prostate Cancer Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Prostate Cancer Vaccines Sales by Country (2021-2032)
  17. 5.5.3 Europe Prostate Cancer Vaccines Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Prostate Cancer Vaccines Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Prostate Cancer Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Prostate Cancer Vaccines Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Prostate Cancer Vaccines Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Prostate Cancer Vaccines Market Facts & Figures by Country
  35. 5.7.1 South America Prostate Cancer Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Prostate Cancer Vaccines Sales by Country (2021-2032)
  37. 5.7.3 South America Prostate Cancer Vaccines Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Prostate Cancer Vaccines Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Prostate Cancer Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Prostate Cancer Vaccines Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Prostate Cancer Vaccines Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Prostate Cancer Vaccines Sales by Type (2021-2032)
  2. 6.1.1 Global Prostate Cancer Vaccines Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Prostate Cancer Vaccines Sales Market Share by Type (2021-2032)
  4. 6.2 Global Prostate Cancer Vaccines Revenue by Type (2021-2032)
  5. 6.2.1 Global Prostate Cancer Vaccines Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Prostate Cancer Vaccines Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Prostate Cancer Vaccines Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Prostate Cancer Vaccines Sales by Application (2021-2032)
  2. 7.1.1 Global Prostate Cancer Vaccines Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Prostate Cancer Vaccines Sales Market Share by Application (2021-2032)
  4. 7.2 Global Prostate Cancer Vaccines Revenue by Application (2021-2032)
  5. 7.2.1 Global Prostate Cancer Vaccines Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Prostate Cancer Vaccines Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Prostate Cancer Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Prostate Cancer Vaccines Value Chain Analysis
  2. 8.1.1 Prostate Cancer Vaccines Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Prostate Cancer Vaccines Production Mode & Process
  5. 8.2 Prostate Cancer Vaccines Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Prostate Cancer Vaccines Distributors
  8. 8.2.3 Prostate Cancer Vaccines Customers
9 Global Prostate Cancer Vaccines Analyzing Market Dynamics
  1. 9.1 Prostate Cancer Vaccines Industry Trends
  2. 9.2 Prostate Cancer Vaccines Industry Drivers
  3. 9.3 Prostate Cancer Vaccines Industry Opportunities and Challenges
  4. 9.4 Prostate Cancer Vaccines Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst